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While our understanding of cancer is be-
coming increasingly nuanced, we still
don’t know why some people get certain
cancers and others do not, nor why can-
cers behave differently in some patients.
‘‘Virtually every man will get prostate can-
cer if he lives long enough.’’ says David
Steffen, Ph.D., director, Bioinformatics
Research, Department of Molecular and
Human Genetics at Baylor University.
‘‘For most it isn’t serious. For a few it
is.’’ According to Steffen, even with
a careful statistical study, it is hard to ver-
ify biomarkers that can be used to distin-
guish the aggressive cancer from the
watchful waiting variety. ‘‘Solving this
problem would be fundamental to all can-
cer research,’’ Steffen says. ‘‘It would be
huge.’’
Redefining Cancer as an
Information Problem
Steffen is hoping that the Cancer Bio-
medical Information Grid (caBIG) will pro-
vide answers by supplying a framework
that allows Baylor to share data efficiently
with the ten other National Cancer Insti-
tute (NCI) prostate cancer SPOREs (short
for Specialized Programs of Research Ex-
cellence). caBIG was established by the
NCI in 2004 to help cancer researchers
use the internet to exchange information
about genetics, treatments, molecular bi-
ology, tissue samples, and clinical trials,
in some cases in real time. The consor-
tium is also developing tools for imaging,
classifying, and analyzing data. The
caBIG consortium now includes over
1000 participants, including federal
agencies, academic centers, and indus-
try. Forty-six NCI-designated cancer cen-
ters are participating, as well as 16 com-
munity cancer centers. This $60 million
information technology initiative com-
pleted its three year pilot phase about
year and a half ago.
Is That an Elephant in the Room?
‘‘We are literally at the precipice of a revo-
lution,’’ says Kenneth H. Buetow, Ph.D.,
director, Center for Biomedical Informat-
ics and Information Technology, National
Cancer Institute. ‘‘It is a revolution that is
overdue in biomedicine.’’
Leaps in computing capacity as well as
a flowering of genetic research have en-
abled laboratories to churn out a huge
amount of data. For example, a plethora
of genome-wide association studies are
uncovering new genes statistically asso-
ciated with disease, but researchers do
not yet know how they function or how
other genes and environmental influences
act upon them. Buetow likens it to the
metaphor of blind men trying to identify
an elephant in a room by feeling its parts.
‘‘There was a pent up demand for this,’’
Buetow says. ‘‘We stepped into this be-
cause the community was asking for
this.’’
According to Dr. H. Kim Lyerly, director
of the Duke Comprehensive Cancer Cen-
ter, researchers attempting to statistically
correlate information gathered from so-
phisticated multigene biomarkers or
gene expression arrays of 30,000 genes
with relatively simple outcomes such as
‘‘would a patient live or die after a certain
number of years’’ and ‘‘how did the pat-
tern of gene expression relate to the treat-
ment the patient received’’ were hitting
a wall. By the time proteomic and meta-
bolic data were layered in, ‘‘the complex-
ity of trying to find correlations or associ-
ations between these typically disparate
data sets made it pretty much impossible
to do,’’ says Lyerly. ‘‘It became increas-
ingly apparent [that] a single strategy to
interrogate across a system won’t be in-
formative as an unbiased approach where
we use a variety of strategies. The tools [of
caBIG] enabled new approaches. To fully
utilize the power of the tools, we needed
a new infrastructure.’’ Duke University is
now utilizing caBIG to analyze gene
expression patterns in breast cancer
patients and compare this to how they
respond to therapy in real time.
Wrangling the Data
caBIG is a federated grid made up of
layers of metadata so users can query
data from different sources via a simple
interface, no matter what software plat-
form they happen to use. It also is a frame-
work for, at current count, 60 different
open source software tools for integrating
clinical information with molecular data.
Tools include image sharing and analysis,
discovery, tissue banking and analysis,
and clinical trial management. These ad-
here to common data standards and
a shared, interoperable infrastructure so
information can be exchanged while pro-
tecting privacy and data security. For ex-
ample, cancer researchers can now ac-
cess pooled clinical trial data from
multiple places, including patient tissue
samples, to investigate rare forms of can-
cer; a handy ability if they do not have
specialized expertise in house. Tissue im-
ages can be annotated by different re-
searchers, so overall patterns and rela-
tionships become apparent. caBIG’s
philosophy is open source development
with ‘‘semantic interoperability’’ in mind,
creating a layered set of standard vocab-
ularies to ensure that everybody de-
scribes the elephant’s trunk in precisely
the same way. Early projects linked to
caBIG include TCGA (The Cancer Ge-
nome Atlas) and REMBRANDT (Reposi-
tory for Molecular Brain Neoplasia Data)
for researchers to share information on
rare brain tumors.
Rolling Out the Grid
In addition to the NCI translational re-
search centers (SPORES), caBIG is now
being rolled out to more community can-
cer centers, 50-odd cooperative groups,
as the NCI-designated centers currently
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US. The consortium is also partnering
with the UK’s National Cancer Research
Institute (NCRI), which has undertaken
a comparable project. Using caBIG,
Duke University and the NCI also have
partnered with the Peking University
Health Science Institute to conduct can-
cer clinical trials in China.
If the framework for information sharing
and collaboration can work for cancer, it
could work for other diseases as well.
Last year, the CardioVascular Research
Grid (http://www.cvrgrid.org) was initi-
ated with an $8.5 million, 4 year NIH grant.
Based at Johns Hopkins University in
Maryland, with partners Ohio State Uni-
versity and the University of California,
San Diego, the grid will give researchers
the ability to swap information about heart
disease and analyze and model patient
data. ‘‘The big picture with caBIG involves
particular tools,’’ says Dr. Joel Saltz, pro-
fessor and chair of Biomedical Informatics
at Ohio State University College of Medi-
cine and the OSU Comprehensive Cancer
Center. ‘‘The bigger picture is that caBIG
will allow large teams of researchers to
work together to develop increasingly ef-
fective treatments for cancer. Existing ap-
proaches to finding treatment have been
piecemeal. caBIG is allowing us to move
from a set of isolated skirmishes to global
strategy.’’
Caveats
According to the ‘‘caBIG Pilot Phase Re-
port 2003–2007,’’ caveats include project
definition and development issues such
as buggy software and sample sizes too
small to get real information. An underly-
ing question is motivation for cooperation.
Lyerly noted that while the caBIG commu-
nity used wide vocabulary standards,
there are ‘‘a number of people [who are]
more methodical or slower adopters.’’
Once software kinks are ironed out, caBIG’s
success will be measured by the rate of
adoption and extent of collaboration
within a community of researchers used
to competing with each other, as well
as by decreasing concerns about intellec-
tual property and patient privacy. But
the decentralized nature of caBIG is its
strength, both for researchers and pa-
tients, because it can easily incorporate
innovative ideas into the greater grid.
For Cancer Patients, It’s about Time
Back in 1997, Joan Schreiner met Joanne
Tyler when both women were undergoing
breast cancer treatment. They became
friends. Schreiner, the tech savvy former
CFO of Shutterfly, had an idea that pa-
tients could use the internet to sign up for
clinical trials where they could get novel
therapies. They presented the concept to
oncologists at the University of California,
San Francisco, whom they knew in con-
nection with their treatment—John Park
and Debu Tripathy, as well as surgeon
Laura Esserman—who agreed to sponsor
the project at the university. ‘‘We knew
we wanted a nonprofit and preferably an
academic institution to at least initially
sponsor this idea and see to its develop-
ment. We didn’t want it to go to a commer-
cial for-profit entity,’’ recalled Joanne
Tyler. ‘‘We were trying to get a patient-
centered service that had integrity and
the interests of patients in mind.’’
Schreiner and Tyler raised an initial budget
of $30,000 including a grant from Amgen
for $10,000. Tyler, now retired, volunteered
time to developing Breastcancertrials.org
(http://www.breastcancertrials.org) with
Elly Cohen, the coordinator who came
on board at UCSF. Then caBIG came
into the picture and linked Breastcancer-
tials.org to caMATCH, its workspace to
develop tools to match patients to clinical
trials. The regional pilot, launched in
2005 and which will run until 2008, was
cosponsored by UCSF and NCI, the
California Breast Cancer Research Pro-
gram, and the Department of Defense
Breast Cancer Research Program. ‘‘It
was a new thing for patients to be involved
in a substantive way.’’ Tyler says. The soft
launch of the new nationwide service is
imminent ‘‘It is due to the effort of a lot
of people, Tyler says. ‘‘I’m really pleased.
I’m only sorry Joan isn’t still around to see
how it has developed.’’
With almost no advertising, a thousand
women signed on Breastcancertrials.org.
‘‘The internet lends itself to national
things,’’ says Dr. Laura Esserman, direc-
tor, Carol Franc Buck Breast Care Center.
‘‘Most people are on the net. Let’s make it
so it is the norm rather than the excep-
tion.’’ Safeway Corporation paid about
$1 million to underwrite the national
launch. The big expense for the project
was the hand coding to put up the trials
on the web. Esserman pointed out that
drug companies spend billions on clinical
trials. ‘‘In pediatric oncology, 70% of pa-
tients participate in clinical trials because
of the way care is given; in adult cancer
trials, only 2%–3%.’’ Esserman says. ‘‘We
want to get that up to 50%.’’ In other
words, they want to make it the norm for
women to consider trial participation.
Breastcancertrials.org will work in tan-
dem with another caBIG-linked program
at UCSF called I-SPY, the next iteration
of an adaptive-design clinical trial to de-
termine biomarkers for the most aggres-
sive cancers and how to tailor treatment
to them. Under I-SPY, women with stage
2 or 3 breast cancer will be assigned to
different arms of a study, receiving stan-
dard therapy or standard therapy plus
novel agents. Based on ongoing results,
regimens will be changed between
groups of patients, so in subsequent iter-
ations they will be reassigned to the study
branches with the most favorable out-
comes. The I-SPY-2 study will commence
in collaboration with multiple drug com-
panies, the FDA, and NCI at about 15
study sites in summer 2009. This study
will treat patients when first diagnosed,
instead of when they present with meta-
static disease, so they have a chance to
be helped by the drugs. ‘‘We are going
to learn which agents are most effective,
and which biomarkers predict that,’’
says Esserman.
‘‘What they can do is come to conclu-
sions, one way or another, sooner than
they could before.’’ says Jane Perlmutter,
who works with breast cancer patients in
the I-SPY program. ‘‘As a patient advo-
cate, I want to push researchers to do
innovative and rigorous things.’’
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